AWKN-P001 - is a novel combined therapeutic consisting of racemic ketamine, delivered IV, and specifically designed psycho-social support to treat Severe Alcohol Use Disorder.
Ketamine is an N-methyl-d-Asparate (NMDA) receptor antagonist with well-established safety and efficacy as an analgesic and anaesthetic. At sub-anaesthetic doses ketamine produces alterations in consciousness, disrupts memory reconsolidation, and delivers downstream neuroplasticity, which when combined with therapy has been proven by Awakn to significantly reduce the probability of relapse for Alcohol Use Disorder.
AWKN-P001 builds on Awakn’s successful phase II a/b clinical trial for ketamine-assisted therapy for Severe AUD in which participants in the active arm achieved 86% abstinence at 6 months post treatment versus 2% pre-trial and 25% in current standard of care.
AWKN-001 Ph3 Trial Design
AWKN-001 Phase III Trial Design
Sign Up for Newsletter